Speaker illustration

Doctor Boldizsar Kovacs

University of Michigan Hospital, Ann Arbor (United States of America)

Member of:

European Society of Cardiology
European Heart Rythm Association

Electrophysiology fellow at University of Michigan in Ann Arbor and student at the University of Oxford for Clinical Trials. I hope to advance the field of electrophysiology by conducting well-designed RCTs in the field.

High incidence of inappropriate alarms in patients with wearable cardioverter-defibrillators: findings from the swiss WCD registry

Event: ESC Congress 2021 - The Digital Experience

Topic: Device Treatment

Session: Ventricular arrhythmias and sudden cardiac death e-posters

Thumbnail

A novel variant in the SLC4A3 gene with high penetrance in a family with short QT Syndrome

Event: EHRA 2021

Topic: Pathophysiology and Mechanisms

Session: New insights in ventricular arrhythmias I

Thumbnail

Two novel variants in the SLC4A3 gene in two families with Short QT Syndrome: the role of cascade screening

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Other Genetic Variants

Session: Ventricular Arrhythmias and Sudden Cardiac Death (SCD) ePosters

Thumbnail

First two MRI guided stereotactic body radiation therapy of recurrent sustained ventricular tachycardia

Event: ESC CONGRESS 2020 - The Digital Experience

Topic: Ablation of Ventricular Arrhythmias

Session: Ventricular Arrhythmias and Sudden Cardiac Death (SCD) ePosters

Thumbnail

Short QT phenotype in a family with genetic variants in the KCNH2 and SLC4A3 genes - The role of prediction tools, whole exome sequencing and genetic cascade screening

Event: EHRA 2019

Topic: Other Genetic Variants

Session: Moderated ePosters 8: channelopathies & cardiomyopathies

Thumbnail

Adequate ICD treatments after the use of the wearable cardioverter-defibrillator - First results from the swiss nationwide WCD registry

Event: EHRA 2019

Topic: Device Treatment

Session: Implantable Cardioverter / Defibrillator

Thumbnail

This platform is supported by

logo Novo Nordisk